contact ussite map
Juvaris Beotherapeutics, Inc.


  • Infectious Diseases Society of America (IDSA) - IDSA 2008 Annual Meeting
  1. Adjuvanting of Fluzone® with JVRS-100 Enhances H1N1, H3N2, and B Influenza Specific Humoral Responses and Increases the Frequency of Multifunctional CD4+ and CD8+ T-cells [PDF 5.2MB]

  • Federation of American Societies of Experimental Biology (FASEB) - Experimental Biology 2008
    Juvaris Posters (April 2008):
  1. Immunotherapy of Acute Leukemia with Cationic Lipid DNA Complexes (JVRS-100)
    [PDF 700KB]
  2. Adjuvanting of Fluzone® with JVRS-100 in Mice, Rabbits and Non-Human Primates Demonstrates Increased Immunogenicity and Dose-Sparing [PDF 777KB]
  3. Inverse relationship between innate and acquired immune responsiveness in mice initially dosed with cationic lipid DNA complexes (JVRS-100) [PDF 738KB]

  • Infectious Diseases Society of America (IDSA) - IDSA 2007 Annual Meeting
    Juvaris Posters (October 2007):
  1. Adjuvanting of existing flu vaccines with Cationic Lipid DNA complexes (JuvImmune™) for cross-protection and dose sparing [PDF 779KB]
  2. Minimal Interspecies Variability in the Innate Immune Response to Cationic Lipid DNA Complexes (JuvImmune™) [PDF 1.25MB]
  3. Plasmacytoid Dendritic Cells Are Dispensable For Antiviral Immune Responses Following Cationic-Lipid-DNA-Complex (CLDC) Adjuvanted Influenza Vaccination [PDF 344KB]
  4. In Vivo Immunogenicity of SIV Vaccine Candidates With and Without a New Immunomodulator in Rhesus Macaques [PDF 6.4MB]
  5. Enhanced Immune Response To Vaccination With Woodchuck Hepatitis Virus (WHV) Surface Antigen (WHsAg) Using Cationic Liposome-DNA Complexes (CLDC) As Adjuvant [PDF 414KB]

^ back to top

© 2014 Juvaris BioTherapeutics.